Lithium is an ineffective therapy for human cyclic hematopoiesis

Area of Science:

• Hematology
• Pharmacology
• Genetics

Background:

• Cyclic hematopoiesis is a rare human disorder characterized by cyclical severe neutropenia every 21 days.
• This condition is associated with significant illness and impacts neutrophil production.
• Previous studies indicated lithium carbonate effectively treated cyclic hematopoiesis in grey collie dogs.

Purpose of the Study:

• To investigate the efficacy of lithium carbonate treatment in human patients diagnosed with cyclic hematopoiesis.
• To determine if lithium therapy can normalize neutrophil count fluctuations in affected individuals.

Main Methods:

• Five human patients with cyclic hematopoiesis were treated with lithium carbonate.
• Therapeutic lithium levels were maintained between 0.5 and 1.0 meq/liter.
• Neutrophil counts were monitored to assess the impact of lithium treatment on cyclical fluctuations.

Main Results:

• Lithium carbonate treatment did not alter the cyclical pattern of neutrophil count fluctuations in the five patients.
• No significant changes were observed in the severity or periodicity of neutropenia during the study.
• The therapeutic lithium levels achieved did not demonstrate a beneficial effect on the disease course.

Conclusions:

• Lithium carbonate is not an effective treatment for cyclic hematopoiesis in humans.
• The mechanism by which lithium carbonate affects hematopoiesis in dogs may not translate to humans.
• Further research is needed to identify effective therapies for human cyclic hematopoiesis.